10-Q: Vicarious Surgical Faces Going Concern, NYSE Listing

Vicarious Surgical reported continued net losses and significant doubt about its ability to continue as a going concern, while addressing NYSE listing non-compliance.

Summary

• Vicarious Surgical Inc. reported a net loss of $28.61 million for the six months ended June 30, 2025, an 11% improvement from the $32.21 million loss in the same period of 2024.
• Loss from operations improved by 13% to $29.27 million for the six months ended June 30, 2025, compared to $33.82 million in the prior year.
• The company's cash, cash equivalents, and short-term investments totaled $23.96 million as of June 30, 2025, which management believes is not sufficient to support operations for the next 12 months.
• Vicarious Surgical received a notice from the NYSE on April 10, 2025, regarding non-compliance with the Minimum Market Capitalization Standard, but its plan for compliance was accepted on July 8, 2025, initiating an 18-month cure period.
• Stephen From was appointed Chief Executive Officer, effective August 7, 2025, with former CEO Adam Sachs transitioning to President.
• The company is pre-revenue generating and is developing a single-port surgical robotic system, the Vicarious Surgical System, which has not yet received FDA authorization.

Sentiment

Score: 3

Explanation: The company faces significant financial distress, including a 'going concern' warning and NYSE listing non-compliance, indicating a high level of risk. While there are some improvements in expense management and a plan accepted by NYSE, the fundamental financial viability is in question without substantial future capital raises and product commercialization.

Positives

• Net loss decreased by 11% to $28.61 million for the six months ended June 30, 2025, compared to $32.21 million in the prior year.
• Loss from operations improved by 13% for the six months ended June 30, 2025, primarily due to reduced personnel-related expenses ($2.54 million decrease) and professional services ($2.90 million decrease).
• Research and development expenses decreased by 12% to $18.47 million for the six months ended June 30, 2025.
• Sales and marketing expenses significantly decreased by 41% to $1.39 million for the six months ended June 30, 2025, largely due to a 40% reduction in average headcount.
• General and administrative expenses decreased by 11% to $9.41 million for the six months ended June 30, 2025.
• The NYSE accepted the company's plan to regain compliance with listing standards, providing an 18-month cure period.

Negatives

• Management has identified substantial doubt about the company's ability to continue as a going concern, as current cash and investments are not sufficient for the next 12 months.
• The company remains pre-revenue generating and has an accumulated deficit of $224.54 million as of June 30, 2025.
• Cash and cash equivalents decreased to $3.91 million as of June 30, 2025, from $9.74 million at December 31, 2024.
• Short-term investments decreased to $20.05 million as of June 30, 2025, from $39.36 million at December 31, 2024.
• Total current assets significantly declined to $26.07 million as of June 30, 2025, from $51.70 million at December 31, 2024.
• Stockholders' equity decreased to $23.06 million as of June 30, 2025, from $46.70 million at December 31, 2024.
• The company is not in compliance with NYSE's Minimum Market Capitalization Standard, indicating a low market valuation and stockholders' equity.
• Material weaknesses in internal control over financial reporting were identified, including improper segregation of duties, issues with account reconciliation, safeguarding assets, IT controls, risk assessment, and documentation.

Risks

• Substantial doubt about the ability to continue as a going concern due to negative cash flows and insufficient capital for the next 12 months.
• Uncertainty regarding the ability to achieve a revenue-generating product and obtain FDA authorization for the Vicarious Surgical System.
• Competition from current and potential competitors with greater financial, technological, production, and marketing resources.
• Dependence on key management personnel, with potential adverse effects if they are lost.
• Inability to raise additional debt or equity capital in sufficient amounts or on acceptable terms, which would adversely affect operating results and prospects.
• Failure to maintain NYSE listing standards, potentially leading to delisting and reduced liquidity, market quotations, news coverage, and future financing ability.
• Risks associated with the success, cost, and timing of product and service development activities.
• Potential for unexpected restrictions and limitations on any authorized product or service offering.
• Impact of changes in U.S. and foreign laws on business operations.
• Challenges in identifying, in-licensing, or acquiring additional technology.
• Difficulties in maintaining existing license agreements and manufacturing arrangements, and scaling manufacturing to commercial quantities.
• Competition with other companies developing products for ventral hernia repair and additional surgical applications, as well as with open surgeries.
• Uncertainty regarding the size and growth potential of target markets for the Vicarious Surgical System.
• Potential adverse impacts on business, financial condition, and results of operations from economic downturns, political, and market conditions, including increased expenses and cost of capital, and supply chain disruptions.
• The ongoing effect of the 1-for-30 reverse stock split on the price or trading of Class A common stock, including potential continued adverse impacts on liquidity.

Future Outlook

The company expects net losses to continue as it invests in commercialization and new product development, with R&D and marketing activities anticipated to increase even after market authorization. It does not expect to generate revenue until FDA authorization of its product candidate. Current cash, cash equivalents, and short-term investments are projected to support operations only into the first quarter of 2026, necessitating substantial additional funding for clinical trials, market authorization, and commercialization.

Management Comments

• Management does not believe that the company's cash, cash equivalents and short-term investments balance at June 30, 2025, of $23,963,000 will be sufficient to support operations for the next 12 months from the date of issuance of these financial statements, raising substantial doubt about the company's ability to continue as a going concern.
• To address capital needs, the company must continue to actively pursue additional equity or debt financing and has been in ongoing discussions with potential investors and banks.
• The company is combining advanced miniaturized robotics, computer science, sensing, and 3D visualization to build a new category of intelligent and affordable, single-port surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery.
• The Vicarious Surgical System is designed with a fundamentally different architecture and proprietary de-coupled actuators to overcome many limitations of open surgery or existing robot-assisted surgical procedures.
• The company plans to file a de novo application with the FDA for use in ventral hernia procedures as its first indication.

Industry Context

Vicarious Surgical operates in the highly competitive and capital-intensive surgical robotics industry. The company aims to differentiate itself by developing a single-port surgical robot designed to overcome limitations of existing systems, such as high upfront costs (up to $2.0 million plus 10-20% annual maintenance), low utilization due to large size and long setup times, limited capabilities (e.g., restricted degrees of freedom, collisions), and difficulty of use requiring extensive surgeon training. The company targets a large market of over 45 million soft tissue surgical procedures annually worldwide, where over 50% are open surgeries and less than 5% use current robot-assisted methods, indicating a significant unmet need for more accessible and capable robotic solutions.

Comparison to Industry Standards

• The company's pre-revenue status and significant accumulated deficit are not uncommon for early-stage medical device companies in the R&D phase, but the 'going concern' warning indicates a more critical financial position compared to established industry players like Intuitive Surgical (maker of da Vinci system) which generate substantial revenue and profit.
• The stated capital costs of existing robotic systems (up to $2.0 million upfront plus 10-20% annual maintenance) align with known industry benchmarks for high-end surgical robots, such as those from Intuitive Surgical, which are a significant barrier to adoption for many facilities.
• The company's focus on addressing limitations like 'limited degrees of freedom' and 'difficulty operating in multiple quadrants' directly targets known challenges with some multi-port robotic systems, aiming for a more versatile solution for procedures like ventral hernia repair.
• The goal of improving 'patient outcomes' and 'cost and efficacy of surgical procedures' positions the company against both traditional open surgery and existing robotic platforms, suggesting a competitive advantage if FDA authorization and commercialization are successful.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently party to any material pending legal proceedings. However, it may become involved in legal proceedings or claims in the ordinary course of business, which could have an adverse impact due to defense and settlement costs, and diversion of management resources.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future capital raises (equity or convertible debt) and the existing universal shelf registration. The 'going concern' warning and NYSE listing non-compliance pose substantial risks to share value and liquidity. The 1-for-30 reverse stock split has had potential adverse impacts on liquidity.
• **Employees**: Headcount reductions, particularly in sales and marketing (40% decrease) and overall (6% decrease), indicate cost-cutting measures that could impact morale and operational capacity. New stock options for the incoming CEO could be a positive for executive incentives, but overall stock-based compensation decreased.
• **Customers (future)**: The development of the Vicarious Surgical System aims to provide a more affordable and capable minimally invasive surgical option, potentially benefiting healthcare providers by addressing limitations of current systems. However, the product is not yet FDA authorized.
• **Creditors**: The 'going concern' warning and declining cash reserves increase credit risk, potentially making future debt financing more difficult or costly.
• **Regulatory Authorities (FDA, NYSE)**: The company is actively engaging with the FDA for product authorization and with the NYSE to maintain its listing, indicating compliance efforts are ongoing and critical for market access and public trading.

Next Steps

• Actively pursue additional equity or debt financing to address capital needs.
• Continue product and service development activities for the Vicarious Surgical System.
• File a de novo application with the FDA for use in ventral hernia procedures as the first indication.
• Continue efforts to regain compliance with NYSE's Minimum Market Capitalization Standard within the 18-month cure period, with quarterly reviews by NYSE.
• Implement additional review controls and processes to remediate identified material weaknesses in internal control over financial reporting, including hiring more experienced personnel.
• Stephen From will assume the role of Chief Executive Officer, effective August 7, 2025.
• Adam Sachs will transition to the role of President, effective August 7, 2025.

Key Dates

Recommendation

The company faces severe financial challenges, explicitly stating 'substantial doubt about its ability to continue as a going concern' and having insufficient cash for the next 12 months. It is pre-revenue, has a significant accumulated deficit, and its cash and investments are rapidly depleting. While expense reductions are noted, they are insufficient to offset the burn rate. The NYSE listing non-compliance, despite an accepted plan, highlights fundamental valuation and equity issues. The need for substantial additional financing in a challenging macroeconomic environment, coupled with the risk of significant dilution or unfavorable terms, makes the investment highly speculative with a high probability of further capital erosion. The management changes, while potentially positive long-term, do not immediately address the critical liquidity and operational risks.

Keywords

Surgical Robotics, Minimally Invasive Surgery, Ventral Hernia Repair, Medical Devices, FDA Authorization, Robotic Surgery, Healthcare Technology, SEC Filing, 10-Q, Going Concern, NYSE Listing, Biotech, Medtech